FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313454951> ?p ?o ?g. }

• W4313454951 abstract "The gut microbiome plays an important role in immune modulation. Specifically, presence or absence of certain gut bacterial taxa has been associated with better antitumor immune responses. Furthermore, in trials using fecal microbiota transplantation (FMT) to treat melanoma patients unresponsive to immune checkpoint inhibitors (ICI), complete responses (CR), partial responses (PR), and durable stable disease (SD) have been observed. However, the underlying mechanism determining which patients will or will not respond and what the optimal FMT composition is, has not been fully elucidated, and a discrepancy in microbial taxa associated with clinical response has been observed between studies. Furthermore, it is unknown whether a change in the microbiome itself, irrespective of its origin, or FMT from ICI responding donors, is required for reversion of ICI-unresponsiveness. To address this, we will transfer microbiota of either ICI responder or nonresponder metastatic melanoma patients via FMT.In this randomized, double-blinded phase Ib/IIa trial, 24 anti-PD1-refractory patients with advanced stage cutaneous melanoma will receive an FMT from either an ICI responding or nonresponding donor, while continuing anti-PD-1 treatment. Donors will be selected from patients with metastatic melanoma treated with anti-PD-1 therapy. Two patients with a good response (≥ 30% decrease according to RECIST 1.1 within the past 24 months) and two patients with progression (≥ 20% increase according to RECIST 1.1 within the past 3 months) will be selected as ICI responding or nonresponding donors, respectively. The primary endpoint is clinical benefit (SD, PR or CR) at 12 weeks, confirmed on a CT scan at 16 weeks. The secondary endpoint is safety, defined as the occurrence of grade ≥ 3 toxicity. Exploratory endpoints are progression-free survival and changes in the gut microbiome, metabolome, and immune cells.Transplanting fecal microbiota to restore the patients' perturbed microbiome has proven successful in several indications. However, less is known about the potential role of FMT to improve antitumor immune response. In this trial, we aim to investigate whether administration of FMT can reverse resistance to anti-PD-1 treatment in patients with advanced stage melanoma, and whether the ICI-responsiveness of the feces donor is associated with its effectiveness.ClinicalTrials.gov: NCT05251389 (registered 22-Feb-2022). Protocol V4.0 (08-02-2022)." @default.
• W4313454951 created "2023-01-06" @default.
• W4313454951 creator A5006585088 @default.
• W4313454951 creator A5012860220 @default.
• W4313454951 creator A5017136846 @default.
• W4313454951 creator A5022157436 @default.
• W4313454951 creator A5035975946 @default.
• W4313454951 creator A5048909726 @default.
• W4313454951 creator A5051903151 @default.
• W4313454951 creator A5055062791 @default.
• W4313454951 creator A5055115810 @default.
• W4313454951 creator A5062791488 @default.
• W4313454951 creator A5075110145 @default.
• W4313454951 creator A5077082267 @default.
• W4313454951 creator A5081360114 @default.
• W4313454951 creator A5084401310 @default.
• W4313454951 creator A5088390068 @default.
• W4313454951 date "2022-12-30" @default.
• W4313454951 modified "2023-10-14" @default.
• W4313454951 title "Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial" @default.
• W4313454951 cites W2072502005 @default.
• W4313454951 cites W2165456770 @default.
• W4313454951 cites W2185075416 @default.
• W4313454951 cites W2197849900 @default.
• W4313454951 cites W2302501749 @default.
• W4313454951 cites W2513533432 @default.
• W4313454951 cites W2547815244 @default.
• W4313454951 cites W2586374101 @default.
• W4313454951 cites W2601055810 @default.
• W4313454951 cites W2616731084 @default.
• W4313454951 cites W2735259022 @default.
• W4313454951 cites W2736166064 @default.
• W4313454951 cites W2753432434 @default.
• W4313454951 cites W2755951643 @default.
• W4313454951 cites W2765314233 @default.
• W4313454951 cites W2766903152 @default.
• W4313454951 cites W2782333299 @default.
• W4313454951 cites W2794616539 @default.
• W4313454951 cites W2797068438 @default.
• W4313454951 cites W2918152867 @default.
• W4313454951 cites W2932174060 @default.
• W4313454951 cites W2938093001 @default.
• W4313454951 cites W2972674410 @default.
• W4313454951 cites W2976599382 @default.
• W4313454951 cites W2979785336 @default.
• W4313454951 cites W2982566732 @default.
• W4313454951 cites W2990381272 @default.
• W4313454951 cites W3004016360 @default.
• W4313454951 cites W3015408469 @default.
• W4313454951 cites W3043703771 @default.
• W4313454951 cites W3045387375 @default.
• W4313454951 cites W3048611368 @default.
• W4313454951 cites W3068877040 @default.
• W4313454951 cites W3090456409 @default.
• W4313454951 cites W3096754838 @default.
• W4313454951 cites W3106917142 @default.
• W4313454951 cites W3111836013 @default.
• W4313454951 cites W3119409060 @default.
• W4313454951 cites W3126208996 @default.
• W4313454951 cites W3209760804 @default.
• W4313454951 cites W4214706689 @default.
• W4313454951 cites W4221050169 @default.
• W4313454951 cites W4225394054 @default.
• W4313454951 doi "https://doi.org/10.1186/s12885-022-10457-y" @default.
• W4313454951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36585700" @default.
• W4313454951 hasPublicationYear "2022" @default.
• W4313454951 type Work @default.
• W4313454951 citedByCount "4" @default.
• W4313454951 countsByYear W43134549512023 @default.
• W4313454951 crossrefType "journal-article" @default.
• W4313454951 hasAuthorship W4313454951A5006585088 @default.
• W4313454951 hasAuthorship W4313454951A5012860220 @default.
• W4313454951 hasAuthorship W4313454951A5017136846 @default.
• W4313454951 hasAuthorship W4313454951A5022157436 @default.
• W4313454951 hasAuthorship W4313454951A5035975946 @default.
• W4313454951 hasAuthorship W4313454951A5048909726 @default.
• W4313454951 hasAuthorship W4313454951A5051903151 @default.
• W4313454951 hasAuthorship W4313454951A5055062791 @default.
• W4313454951 hasAuthorship W4313454951A5055115810 @default.
• W4313454951 hasAuthorship W4313454951A5062791488 @default.
• W4313454951 hasAuthorship W4313454951A5075110145 @default.
• W4313454951 hasAuthorship W4313454951A5077082267 @default.
• W4313454951 hasAuthorship W4313454951A5081360114 @default.
• W4313454951 hasAuthorship W4313454951A5084401310 @default.
• W4313454951 hasAuthorship W4313454951A5088390068 @default.
• W4313454951 hasBestOaLocation W43134549511 @default.
• W4313454951 hasConcept C126322002 @default.
• W4313454951 hasConcept C143121216 @default.
• W4313454951 hasConcept C143998085 @default.
• W4313454951 hasConcept C168563851 @default.
• W4313454951 hasConcept C203014093 @default.
• W4313454951 hasConcept C203092338 @default.
• W4313454951 hasConcept C2777658100 @default.
• W4313454951 hasConcept C2777701055 @default.
• W4313454951 hasConcept C2779134260 @default.
• W4313454951 hasConcept C2779984678 @default.
• W4313454951 hasConcept C2780851360 @default.
• W4313454951 hasConcept C2911091166 @default.
• W4313454951 hasConcept C31760486 @default.
• W4313454951 hasConcept C502942594 @default.

• next